HQ Team
January 30, 2023: Dr. Reddy’s unveiled its difluprednate ophthalmic emulsion in the US market for treating inflammation and pain associated with eye surgery.
Difluprednate ophthalmic belongs to a class of medications called corticosteroids. It works by stopping the release of certain natural substances that cause swelling and pain.
The side effects may include blurred vision, decreased vision, and seeing glare from lights or the sun. Difluprednate eye drops may increase the risk of developing glaucoma when used longer.
According to a company statement, the drug is a generic therapeutic equivalent to Durezol and was introduced to the US market after FDA approval.
The Durezol brand and generic had US sales of approximately $40 million for the most recent twelve months that ended in November 2022, according to the research firm IQVIA. It is available in 5 ml bottles in case packs of 24.
Dr Reddy’s Laboratories is headquartered in Hyderabad, India. It offers a portfolio of products and services, including APIs, generics, branded generics, biosimilars and OTC.
The company’s primary therapeutic areas are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Its primary markets include – the US, India, Russia & CIS countries, China, Brazil and Europe.
Dr Reddy’s consolidated profit after tax for the quarter that ended December 31, 2022, rose 77% to INR 1,247.1 crore as against Rs 706.5 crore in the same quarter a year ago.
